Osimertinib confers potent binding affinity to EGFR kinase domain duplication

Int J Cancer. 2019 Nov 15;145(10):2884-2885. doi: 10.1002/ijc.32617. Epub 2019 Aug 23.

Authors

Rui Jin¹, Jie Li², Zhou Jin¹, Yuefei Lu¹, Yang W Shao³, Wen Li¹, Guofang Zhao², Yang Xia¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
² Department of Thoracic Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
³ Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada.

PMID: 31393596
DOI: 10.1002/ijc.32617

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / pharmacology*
Acrylamides / therapeutic use
Aniline Compounds / pharmacology*
Aniline Compounds / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Crystallography, X-Ray
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / chemistry
ErbB Receptors / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Molecular Docking Simulation
Protein Domains / genetics
Protein Kinase Inhibitors / pharmacology*
Protein Kinase Inhibitors / therapeutic use

Substances

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
osimertinib
EGFR protein, human
ErbB Receptors